An integrated humoral and cellular response is elicited in pancreatic cancer by α-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen

International Journal of Cancer

Volumn 125, Issue 3, 2009, Pages 639-648

  Cappello, Paola ^a,b   Tomaino, Barbara ^a,b   Chiarle, Roberto ^a   Ceruti, Patrizia ^a,b   Novarino, Anna ^a   Castagnoli, Carlotta ^c   Migliorini, Paola ^d   Perconti, Giovanni ^e,f   Giallongo, Agata ^f   Milella, Michele ^g   Monsurrò, Vladia ^h   Barbi, Stefano ^h   Scarpa, Aldo ^h   Nisticò, Paola ^g   Giovarelli, Mirella ^a,b   Novelli, Francesco ^a,b  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c CTO HOSPITAL   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

^f CNR   (Italy)

^g REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^h UNIVERSITY OF VERONA   (Italy)

Author keywords

Alpha enolase; B cell response; Human; Pancreatic ductal adenocarcinoma; T cell response; Tumor antigen

Indexed keywords

ALPHA ENOLASE; GAMMA INTERFERON; IMMUNOGLOBULIN G; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS DUCT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; DENDRITIC CELLS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; INTERFERON-GAMMA; KERATINOCYTES; MICE; PANCREAS; PANCREATIC NEOPLASMS; PHOSPHOPYRUVATE HYDRATASE; SKIN; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

EID: 67650035112     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24355     Document Type: Article

References (50)

1. Laheru D, Jaffee EM. Immunotherapy for pancreatic cancer - science driving clinical progress. Nat Rev Cancer 2005;5:459-67.
2. Cavallo F, Calogero RA, Forni G. Are oncoantigens suitable targets for anti-tumour therapy? Nat Rev Cancer 2007;7:707-13.
3. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
4. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
5. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006;90:1-50.
6. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007;67:9518-27.
7. Berd D, Maguire HC, Jr, Mastrangelo MJ. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 1986;46:2572-7.
8. Holmberg LA, Sandmaier BM. Theratope vaccine (STn-KLH). Expert Opin Biol Ther 2001;1:881-91.
9. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler JG, Emens LA, Reilly RT, Jaffee EM. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005;201:1591-602.
10. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, Hege K, Jaffee E. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008;14:1455-63.
11. Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E, Whiteside T, Osborne J, Kim H, Day R, Troetschel M, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 2005;54:254-64.
12. Jung S, Schluesener HJ. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 1991;173:273-6.
13. Nakatsura T, Senju S, Ito M, Nishimura Y, Itoh K. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 2002;32:826-36.
14. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Soreide O, Eriksen JA, Moller M, Baksaas I, Lothe RA, Saeterdal I, Gaudernack G. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001;92:441-50.
15. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008;44:46-53.
16. Le Naour F. Contribution of proteomics to tumor immunology. Proteomics 2001;1:1295-302.
17. Tureci O, Sahin U, Pfreundschuh M. Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today 1997;3:342-9.
18. Novelli F, Tomaino B, Cappello P. Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma.WO/2008/037792, 2008. Available at: http://www.wipo.int/pctdb/en/wo.jsp?WO5 2008037792.
19. De Luca M, Pellegrini G. The importance of epidermal stem cells in keratinocyte-mediated gene therapy. Gene Ther 1997;4:381-3.
20. Testoni B, Borrelli S, Tenedini E, Alotto D, Castagnoli C, Piccolo S, Tagliafico E, Ferrari S, Vigano MA, Mantovani R. Identification of new p63 targets in human keratinocytes. Cell Cycle 2006;5:2805-11.
21. Truong AB, Khavari PA. Control of keratinocyte proliferation and differentiation by p63. Cell Cycle 2007;6:295-9.
22. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
23. Moscato S, Pratesi F, Sabbatini A, Chimenti D, Scavuzzo M, Passatino R, Bombardieri S, Giallongo A, Migliorini P. Surface expression of a glycolytic enzyme, alpha-enolase, recognized by autoantibodies in connective tissue disorders. Eur J Immunol 2000;30:3575-84.
24. Giallongo A, Feo S, Moore R, Croce CM, Showe LC. Molecular cloning and nucleotide sequence of a full-length cDNA for human alpha enolase. Proc Natl Acad Sci USA 1986;83:6741-5.
25. Cappello P, Fraone T, Barberis L, Costa C, Hirsch E, Elia AR, Caorsi C, Musso T, Novelli F, Giovarelli M. CC-chemokine ligand 16 induces a novel maturation program in human immature monocytederived dendritic cells. J Immunol. 2006;177:6143-51.
26. Tomaino B, Cappello P, Capello M, Fredolini C, Ponzetto A, Novarino A, Ciuffreda L, Bertetto O, De Angelis C, Gaia E, Salacone P, Milella M, et al. Autoantibody signature in human ductal pancreatic adenocarcinoma. J Proteome Res 2007;6:4025-31.
27. Farrow B, Sugiyama Y, Chen A, Uffort E, Nealon W, Mark Evers B Inflammatory mechanisms contributing to pancreatic cancer development. Ann Surg 2004;239:763-9; discussion 9-71.
28. Lopez-Alemany R, Longstaff C, Hawley S, Mirshahi M, Fabregas P, Jardi M, Merton E, Miles LA, Felez J. Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-Enolase. Am J Hematol 2003;72:234-42.
29. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003;95:516-25.
30. Ramanathan A, Wang C, Schreiber SL. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci USA 2005;102:5992-7.
31. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996;271:32529-37.
32. Chang GC, Liu KJ, Hsieh CL, Hu TS, Charoenfuprasert S, Liu HK, Luh KT, Hsu LH, Wu CW, Ting CC, Chen CY, Chen KC, et al. Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. Clin Cancer Res 2006;12:5746-54.
33. Takashima M, Kuramitsu Y, Yokoyama Y, Iizuka N, Fujimoto M, Nishisaka T, Okita K, Oka M, Nakamura K. Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma: association with tumor progression as determined by proteomic analysis. Proteomics 2005;5:1686-92.
34. Forooghian F, Adamus G, Sproule M, Westall C, O'Connor P. Enolase autoantibodies and retinal function in multiple sclerosis patients. Graefe's Arch Clin Exp Ophthalmol 2007;245:1077-84.
35. Tanaka Y, Nakamura M, Matsui T, Iizuka N, Kondo H, Tohma S, Masuko K, Yudoh K, Nakamura H, Nishioka K, Koizuka I, Kato T. Proteomic surveillance of autoantigens in relapsing polychondritis. Microbiol Immunol 2006;50:117-26.
36. Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P, Moyes D, Taylor PC, Venables PJ Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005;7:R1421-9.
37. O'Dwyer DT, Smith AI, Matthew ML, Andronicos NM, Ranson M, Robinson PJ, Crock PA. Identification of the 49-kDa autoantigen associated with lymphocytic hypophysitis as alpha-enolase. J Clin Endocrinol Metab 2002;87:752-7.
38. Orth T, Kellner R, Diekmann O, Faust J, Meyer zum Buschenfelde KH, Mayet WJ. Identification and characterization of autoantibodies against catalase and alpha-enolase in patients with primary sclerosing cholangitis. Clin Exp Immunol 1998;112:507-15.
39. Walter M, Berg H, Leidenberger FA, Schweppe KW, Northemann W. Autoreactive epitopes within the human alpha-enolase and their recognition by sera from patients with endometriosis. J Autoimmun 1995;8:931-45.
40. Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF. Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry 1991;30:1682-91.
41. Pancholi V. Multifunctional alpha-enolase: its role in diseases. Cell Mol Life Sci 2001;58:902-20.
42. Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/ II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci USA 2007;104:12837-42.
43. Jager E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, Ayyoub M, Ritter E, Ritter G, Jager D, Panicali D, Hoffman E, et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci USA 2006;103:14453-8.
44. Walsh TJ, Hathorn JW, Sobel JD, Merz WG, Sanchez V, Maret SM, Buckley HR, Pfaller MA, Schaufele R, Sliva C, Navarro E, Lecciones J, et al. Detection of circulating Candida enolase by immunoassay in patients with cancer and invasive candidiasis. N Engl J Med 1991;324:1026-31.
45. Sundstrom P, Aliaga GR. Molecular cloning of cDNA and analysis of protein secondary structure of Candida albicans enolase, an abundant, immunodominant glycolytic enzyme. J Bacteriol 1992;174:6789-99.
46. Sundstrom P, Aliaga GR. A subset of proteins found in culture supernatants of Candida albicans includes the abundant, immunodominant, glycolytic enzyme enolase. J Infect Dis 1994;169:452-6.
47. Mitsutake K, Kohno S, Miyazaki T, Miyazaki H, Maesaki S, Koga H. Detection of Candida enolase antibody in patients with candidiasis. J Clin Lab Anal 1994;8:207-10.
48. Sato N, Nabeta Y, Kondo H, Sahara H, Hirohashi Y, Kashiwagi K, Kanaseki T, Sato Y, Rong S, Hirai I, Kamiguchi K, Tamura Y, et al. Human CD8 and CD4 T cell epitopes of epithelial cancer antigens. Cancer Chemother Pharmacol 2000;46 (Suppl):S86-90.
49. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008;8:59-73.
50. Kroemer G, Zitvogel L. Death, danger, and immunity: an infernal trio. Immunol Rev 2007;220:5-7.